Saraymen Esma, Erdem Yakut, Akalın Hilal, Taşçıoğlu Nazife, Saraymen Berkay, Çelik Serhat, Özdemir Yeşim, Kaynar Leylagül, Çetin Mustafa, Özkul Yusuf
Central Research Facility Application and Research Center, Abdullah Gül University, Kayseri, Türkiye.
Betül-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Türkiye.
Cell Mol Biol (Noisy-le-grand). 2024 Nov 27;70(11):39-45. doi: 10.14715/cmb/2024.70.11.5.
Homeobox (HOX) transcript antisense RNA (HOTAIR) and HOX genes are reported to be more expressed in various cancers in humans in recent studies. The role of HOTAIR and HOXD genes in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) is not well known. In this study, expression levels of HOXD8, HOXD9 and HOXD11 from HOXD gene family and HOTAIR were determined from peripheral blood samples of 30 AML and 30 CML patients and 20 healthy volunteers by quantitative Real Time PCR. We determined that the expression levels of HOXD9 and HOXD11 in the AML patients were significantly lower than the control group (p<0.001 and p=0.002, respectively). There was no significant difference in the expression levels of HOTAIR and HOXD8 when compared to the control group. In the CML patients there was a significant increase in the expression level of HOTAIR when compared to the control group (p=0.002). The expression levels of HOXD9 and HOXD11 were found to be significantly lower than the control group (p<0.001). Our study showed that HOTAIR may not be a biomarker in the diagnosis and is not significantly correlated with the clinicopathological prognostic characteristics of AML. Additionally; it can be said that HOTAIR is oncogenic by suppressing the expression of HOXD9 and HOXD11 but not HOXD8 in CML patients. The expression profiles of HOTAIR may be a potential biomarker in the diagnosis of CML patients in predicting and monitoring drug resistance.
近期研究报道，同源框（HOX）转录反义RNA（HOTAIR）和HOX基因在人类多种癌症中表达更高。HOTAIR和HOXD基因在急性髓系白血病（AML）和慢性髓系白血病（CML）中的作用尚不清楚。在本研究中，通过定量实时PCR从30例AML患者、30例CML患者和20名健康志愿者的外周血样本中测定了HOXD基因家族中HOXD8、HOXD9和HOXD11以及HOTAIR的表达水平。我们发现AML患者中HOXD9和HOXD11的表达水平显著低于对照组（分别为p<0.001和p=0.002）。与对照组相比，HOTAIR和HOXD8的表达水平无显著差异。在CML患者中，与对照组相比HOTAIR的表达水平显著升高（p=0.002）。发现HOXD9和HOXD11的表达水平显著低于对照组（p<0.001）。我们的研究表明，HOTAIR可能不是AML诊断中的生物标志物，且与AML的临床病理预后特征无显著相关性。此外，可以说HOTAIR通过抑制CML患者中HOXD9和HOXD11而非HOXD8的表达具有致癌性。HOTAIR的表达谱可能是预测和监测CML患者耐药性的诊断中的潜在生物标志物。
